The Individual Therapy for Patients With Wilson's Disease

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03957720
Collaborator
(none)
400
1
6
69.6
5.7

Study Details

Study Description

Brief Summary

Based on the genotype characteristics and genotype-phenotype-treatment prognosis data of Chinese WD patients, this study intends to further optimize the treatment regimen of Chinese WD patients and formulate individualized treatment regimens for each genotype, so as to further improve the prognosis of patients.

Condition or Disease Intervention/Treatment Phase
Early Phase 1

Detailed Description

The purpose of the study is to evaluate treatment regimen efficacy based on different mutations, and Zinc treatment in presymptomatic WD patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
The Individual Therapy for Patients With Wilson's Disease
Actual Study Start Date :
Mar 15, 2019
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: homo-R778L

When patients carrying homo-R778L mutation are in hospital, they receive DMPS treatment. Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;

Drug: DMPS
Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
Other Names:
  • Sodium Dimercaptosulphonate
  • Drug: DMSA
    Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
    Other Names:
  • Dimercaptosuccinic Acid
  • Experimental: R778L+truncation mutation

    When patients carrying R778L and truncation mutation are in hospital, they receive DMPS treatment. Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;

    Drug: DMPS
    Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
    Other Names:
  • Sodium Dimercaptosulphonate
  • Drug: DMSA
    Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
    Other Names:
  • Dimercaptosuccinic Acid
  • Experimental: Homo-P992L

    When patients carrying Homo-P992L mutation are in hospital, they receive DMPS treatment. Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;

    Drug: DMPS
    Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
    Other Names:
  • Sodium Dimercaptosulphonate
  • Drug: DMSA
    Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
    Other Names:
  • Dimercaptosuccinic Acid
  • Experimental: P992L+truncation mutation

    When patients carrying P992L and truncation mutation are in hospital, they receive DMPS treatment. Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form:DMSA:750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form:DMSA:35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;

    Drug: DMPS
    Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
    Other Names:
  • Sodium Dimercaptosulphonate
  • Drug: DMSA
    Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
    Other Names:
  • Dimercaptosuccinic Acid
  • Experimental: T935M+other point mutations

    When patients carrying T935M and other point mutations are in hospital, they randomly receive DMPS or penicillamine treatment; Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; Dosage Form: penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years; When being off hospital, they receive DMSA treatment or penicillamine. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;

    Drug: DMPS
    Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
    Other Names:
  • Sodium Dimercaptosulphonate
  • Drug: Penicillamine
    Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;

    Drug: DMSA
    Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
    Other Names:
  • Dimercaptosuccinic Acid
  • Experimental: Presymptomatic patients with Wilson's disease

    According to different age group, they receive various dosage of Zinc Gluconate treatment. Patient aged≤6 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:BID, Zinc Gluconate Duration: 5 years; Patient aged from 6 to 14 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years; Patient aged≥14 years,Dosage Form: Zinc Gluconate: 210mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years;

    Drug: Zinc gluconate
    Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:BID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:TID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 210mg per time,Zinc Frequency:TID,Zinc Duration: 5 years;

    Outcome Measures

    Primary Outcome Measures

    1. Serum ceruloplasmin [Five years]

      Serum ceruloplasmin concentration will be analysed using a validated assay

    2. 24-hour urine copper [Five years]

      24-hour urinary copper excretion is to be measured

    3. serum copper [Five years]

      serum copper will be analysed using a validated assay

    4. White blood cell [Five years]

      The white blood cell will be evaluated using a validated assay

    5. Platelet count [Five years]

      The platelet count will be evaluated using a validated assay

    6. urine protein level [Five years]

      The urine protein level will be collected using a validated assay

    7. Alanine transaminase [Five years]

      The concentration of alanine transaminase will be collected using a validated assay

    8. blood creatinine [Five years]

      The concentration of blood creatinine will be tested using a validated assay

    9. international normalized ratio [Five years]

      The international normalized ratio will be analyzed

    10. hepatic fibrosis markers test [Five years]

      The concentrations of procollagen III, collage IV and hyaluronidase will be evaluated using a validated assay

    11. bone mineral density test [Five years]

      The bone mineral density will be tested using the dual energy X ray absorptiometry

    12. Abdominal ultrasound [Five years]

      The abdominal ultrasound will be collected

    13. Urinary ultrasound [Five years]

      The urinary ultrasound will be analyzed in patients

    14. Cranial MRI scan [Five years]

      The cranial MRI scan will be analyzed in patients

    15. Unified Wilson's disease rating scale [Five years]

      The Unified Wilson's disease rating scale consist of three subscales, including neurological part (0~112), liver functional part (0~36) and mental state part (0~76). Three subscale scores are summed to compute a total score. The higher values represent a worse outcome

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Genetic diagnosis of Wilson's disease

    • Presymptomatic patients with Wilson's disease

    Exclusion Criteria:
    • Movement disorder due to other definite causes instead of Wilson's disease

    • Severe Lung, kidney or liver disease

    • Neoplastic Disease

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 econd Affiliated Hospital,Zhejiang University School of Medicine Hangzhou Zhejiang China 310009

    Sponsors and Collaborators

    • Second Affiliated Hospital, School of Medicine, Zhejiang University

    Investigators

    • Principal Investigator: Zhi-Ying Wu, MD&PhD, Zhejiang University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Second Affiliated Hospital, School of Medicine, Zhejiang University
    ClinicalTrials.gov Identifier:
    NCT03957720
    Other Study ID Numbers:
    • WuZYLab-WD
    First Posted:
    May 21, 2019
    Last Update Posted:
    May 21, 2019
    Last Verified:
    May 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 21, 2019